

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
VAN67 P-329

SERIAL NO. 10/563, 616

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S)
George F. Vande Woude et al.

FILING DATE
August 9, 2006

GROUP
1615



U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPRO- PRIATE |
|---------------------|-----------------|------------|------------------|-------|---------------|---------------------------------------|
| | 5 6 3 9 7 2 5 | 06/17/1997 | O'Reilly et al. | | | |
| | 6 5 7 6 6 3 2 | 06/10/2003 | Goldstein et al. | | | |
| | 5 9 9 7 6 6 6 | 12/07/1999 | Goldberg et al. | | | |
| | 5 7 0 7 6 2 4 | 01/13/1998 | Nickoloff et al. | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLA- TION |
|---------------------|-----------------|----------|---------|-------|---------------|------------------|
| | | | | | | Y N |
| | 0 1 6 6 1 4 4 | 09/13/01 | PCT | | | |
| | 0 2 0 7 6 4 9 6 | 10/03/02 | PCT | | | |
| | 0 3 0 1 8 7 4 8 | 03/06/03 | PCT | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| EXAMINER INITIAL | |
|---------------------|---|
| | Allegrini, G. et al., "The Angiogenesis Inhibitor Thrombospondin-1 Plus Irinotecan Significantly Inhibit Tumor Growth in Human Colon Tumor Bearing Nude Mice," Proceedings of the American Association for Cancer Research, Volume 41, March 2000, page 813 |

| EXAMINER | DATE CONSIDERED |
|---|-----------------|
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /1. B.G.

**FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE**
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO.
VAN67 P-329

SERIAL NO. 10/563, 616
APPLICANT(S)

George F. Vande Woude et al.

FILING DATE

August 9, 2006

GROUP

1615

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPRO- PRIATE |
|---------------------|-----------------|------|------|-------|---------------|---------------------------------------|
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLA- TION |
|---------------------|-----------------|----------|---------|-------|---------------|------------------|
| | | | | | | Y N |
| | 0 2 1 8 3 8 0 | 03/07/02 | PCT | | | |
| | 0 2 1 8 3 7 9 | 03/07/02 | PCT | | | |
| | 9 9 4 3 3 1 1 | 09/02/99 | PCT | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| EXAMINER INITIAL | |
|---------------------|--|
| | F.Y.F.L. De Vos et al., "A phase I dose escalating study of the angiogenesis inhibitor thrombospondin-1 mimetic (abt-510) in patients with advanced cancer," European Journal of Cancer, Volume 38, November 2002, pages S78-S79 |
| | Armstrong, L.C. et al., "Thrombospondins 1 and 2 function as inhibitors of angiogenesis," Matrix Biology, Volume 22, March 2003, pages 63-71 |
| | Guo, N-H. et al., "Antiproliferative and Antitumor Activities of D-Reverse Peptides Derived From the Second Type-1 Repeat of Thrombospondin-1," Journal of Peptide Research, Volume 50, September 1997, pages 210-221 |

| EXAMINER | DATE CONSIDERED |
|---|-----------------|
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. (Form PTO-1449 (6-4)) L.B.G

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
VAN67 P-329

SERIAL NO. 10/563, 616

APPLICANT(S)
George F. Vande Woude et al.

FILING DATE
August 9, 2006

GROUP
1615

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPRO- PRIATE |
|---------------------|-----------------|------|------|-------|---------------|---------------------------------------|
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLA- TION |
|---------------------|-----------------|------|---------|-------|---------------|------------------|
| | | | | | | Y N |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| EXAMINER INITIAL | |
|---------------------|--|
| | Streit, Michael et al., "Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas," American Journal of Pathology, Volume 155, August 1999, pages 441-452 |
| | Reiher, Frank K. et al., "Inhibitions of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics," International Journal of Cancer, Volume 98, April 10, 2002, pages 682-689 |
| | Feige, JJ, "The thrombospondins: "Multimodular proteins with angiogenesis inhibiting effects," Pathologie Biologie, Volume 47, No. 4, April 1999, pages 339-344 |
| | Lawler, Jack, "Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth," Journal of Cellular and Molecular Medicine," Volume 6, January 2002, pages 1-12 |
| | Henkin, Jack et al., "Tumor inhibition by anti-angiogenic TSP-1 mimetic peptides," Proceedings of the American Association for Cancer Research Annual Meeting, Volume 43, March 2002, page 180 |

| EXAMINER | DATE CONSIDERED |
|---|-----------------|
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH (Form PTO-1449 [6-4]) L.B.G.

**FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE**
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO.
VAN67 P-329

SERIAL NO. 10/563, 616

APPLICANT(S)
George F. Vande Woude et al.

FILING DATE
August 9, 2006

GROUP
1615

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPRO- PRIATE |
|---------------------|-----------------|------|------|-------|---------------|---------------------------------------|
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLA- TION |
|---------------------|-----------------|------|---------|-------|---------------|------------------|
| | | | | | | Y N |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| EXAMINER INITIAL | |
|---------------------|--|
| | Vailhe, Bruno et al., "Thrombospondins as anti-angiogenic therapeutic agents," Current Pharmaceutical Design, Volume 9, 2003, pages 583-588 |
| | Iruela-Arispe, M. L. et al., "Inhibition of Angiogenesis by Thrombospondin-1 is Mediated by 2 Independent Regions Within the Type 1 Repeats," American Heart Association, Volume 100, September 28, 1999, pages 1423-1431 |
| | Database WPI, Section Ch, Week 200347, Derwent Publications No date |
| | Database WPI, Section Ch, Week 200364, Derwent Publicaitons No date |
| | Zhang, Yu Wen et al., "Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation," Proceedings of the National Academy of Sciences of the United States of America, Volume 100, October 28, 2003, pages 12718-12723 |

| | |
|---|-------------------------------|
| EXAMINER /Laura B. Goddard/ | DATE CONSIDERED 01/07/2010 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. (Form PTO-1449 (6-4)) L.B.G